NCT06494345View on ClinicalTrials.gov

A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

January 15, 2023

Primary Completion Date

June 9, 2024

Study Completion Date

June 9, 2024

Conditions
Allergic Asthma
Interventions
BIOLOGICAL

Genolair, solution for subcutaneous administration, 150 mg

Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration

BIOLOGICAL

Genolair, lyophilisate for the preparation of solution for subcutaneous administration

Genolair (omalizumab), lyophilisate for the preparation of solution for subcutaneous administration, 150 mg for single subcutaneous administration

BIOLOGICAL

Xolair®, solution for subcutaneous administration, 150 mg

Xolair® (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration

Trial Locations (1)

117556

"State budgetary healthcare institution of the city of Moscow City Clinic No. 2 of the Moscow Health Department", Moscow

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY